Board

Brad is the founder of GlyTherix. He has a PhD in protein chemistry, led research groups in government agencies, universities and hospitals and has founded three companies. He was joint recipient of the 2015 Eureka Prize, for Interdisciplinary Research. He has co-authored over 120 peer reviewed papers and book chapters and seven patents.

A seasoned financial professional having worked in chemical, telecommunications and financial services industries. He has held various senior/board positions, for listed and unlisted companies, in Australia, UK and Hong Kong, including GFA International Limited, Swire Blanch Limited and OAMPS Limited.

Mr Millard is a consultant with extensive experience in providing strategic advice to both listed and unlisted companies in Australia and overseas. He has assisted various companies in raising seed capital and with their ultimate listing. He is similarly assisting the Company.